Copenhagen, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Gene therapy's biggest obstacle isn't science - it's manufacturing. While the field races forward with breakthrough treatments, production remains stuck ...

The need for γ-retroviral (gRV) vectors with a self-inactivating (SIN) design for clinical application has prompted a shift in methodology of vector manufacturing from the traditional use of stable ...

HIV particles produced by cells superinfected with other viruses, such as Moloney murine leukaemia virus, herpes simplex virus and vesicular stomatitis virus (VSV), display an expanded cell tropism ...